公开(公告)号：US20230355727A1

公开(公告)日：2023-11-09

申请号：US18144968

申请日：2023-05-09

Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.

Inventor： Joab CHAPMAN ,  Efrat SHAVIT STEIN ,  Ygal ROTENSTREICH ,  Ifat SHER ROSENTHAL

IPC: A61P27/02 ,  A61K38/55 ,  A61K9/00

CPC classification number: A61K38/55 ,  A61K9/0048 ,  A61P27/02

Abstract: Ophthalmic formulations comprising a PAR1 antagonist and/or an agent that interferes with an interaction of PAR1 and a protease (e.g., thrombin), and an ophthalmically acceptable carrier, and uses thereof in treating or preventing retinal pathologies such as retinal degeneration, are provided. The agent can be, for example, a peptide conjugate represented by Formula I, as defined in the specification.

公开(公告)号：US20190153031A1

公开(公告)日：2019-05-23

申请号：US16306920

申请日：2017-06-02

Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.

Inventor： Nicola MAGGIO ,  Joab CHAPMAN ,  Efrat SHAVIT STEIN

IPC: C07K5/103 ,  A61P37/06 ,  C07K5/113 ,  A61P25/00 ,  A61P29/00 ,  C07K7/06

Abstract: An isolated peptide of up to 6 amino acids comprising an amino acid sequence which inhibits binding of an endothelial cell protein C receptor (EPCR) ligand to the EPCR is disclosed. Also disclosed is an isolated peptide comprising an amino acid sequence which inhibits binding of an endothelial cell protein C receptor (EPCR) ligand to the EPCR, wherein the peptide comprises a modification in at least one amino acid. Also disclosed is a molecule comprising an amino acid sequence which inhibits binding of an endothelial cell protein C receptor (EPCR) ligand to the EPCR attached to a heterologous moiety. Pharmaceutical compositions and methods of treatment are also disclosed.